Results 141 to 150 of about 27,184 (256)

Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts [PDF]

BACKGROUND: Integrase strand-transfer inhibitors (INSTIs) and tenofovir alafenamide have been associated with weight gain in several clinical trials and observational cohorts.
Abela, I, Bansi-Matharu, L, Bissio, E, Byonanebye, DM, Castagna, A, Cohen, C, d'Arminio Monforte, A, De Wit, S, Fontas, E, Grabmeier-Pfistershammer, K, Hosein, SR, Jaschinski, N, Law, M, Maltez, F, Mocroft, A, Mussini, C, Peters, L, Petoumenos, K, Polizzotto, MN, Rauch, A, Ryom, L, Sarcletti, M, Vannappagari, V, Wasmuth, JC, Wit, F   +24 more
core  

Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies. [PDF]

J Infect Dis
Cox S, Andreatta K, Hendricks MR, Li J, Kintu A, Brown LB, Carter CC, Callebaut C.   +7 more
europepmc   +1 more source

Evaluating the Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube. [PDF]

Open Forum Infect Dis
Mercure J, Bey K, Gillett E, Pearson JC, McCluskey SM, Rock AE.   +5 more
europepmc   +1 more source

Efficacy and tolerability of tenofovir alafenamide fumarate prophylaxis in HBV-infected individuals receiving chemo/immunosuppressive therapy. [PDF]

Hepatol Forum
Dilber F, Durak S, Unsal Y, Demir M, Yildirim AE, Ellik ZM, Mehdiyev S, Adanir H, Yapali S, Demirtas CO, Ucbilek E, Balaban Y, Ekmen N, Gokcan H, Koc ES, Dincer D, Sezgin O, Simsek H, Tozun N, Arslan M, Idilman R, Etik DO, Gokcen P, Ari D, Ozdil K, Akdogan M, Boyacioglu S.   +26 more
europepmc   +1 more source

Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV in Asia: 24-Month findings from the observational BICSTaR study. [PDF]

Medicine (Baltimore)
Yang CJ, Kim YS, Choi JY, Choy CY, Lu PL, Tsai HC, Ryu J, Harrison R, Chang J, Mo B, Lee SH, Hung CC.   +11 more
europepmc   +1 more source

Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV: A Real-World Data from the Spanish BICSTaR Cohort. [PDF]

HIV AIDS (Auckl)
Inciarte A, Miralles C, Silva-Klug A, Revollo B, García Deltoro M, Portilla J, Antela A, Castaño Carracedo MÁ, De Álvaro C, Ramroth J, González-Cordón A, Mallolas J.   +11 more
europepmc   +1 more source

Higher rates of triple-class virological failure in perinatally HIV-infected teenagers compared with heterosexually infected young adults in Europe [PDF]

, 2017
, , Lodwick, R.
core   +1 more source

Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment. [PDF]

Viruses
Tahmaz A, Yıldız Dikmen M, Yıldırım F, Öztürk Kaygusuz T, Karabay O, Çelen MK, Alkan S, Damar Çakırca T, Akgül F, Akhan S, Gürbüz E, Özer Balin Ş, Çelik M, Çabalak M.   +13 more
europepmc   +1 more source

Correction: Impact of bictegravir/emtricitabine/tenofovir alafenamide on health-related quality of life and economic outcomes in HIV care: Substudy of the BIC-NOW clinical trial. [PDF]

PLoS One
Sequera-Arquelladas S, Vivancos MJ, Vinuesa D, Collado A, Santos IL, Sorni P, Cabello-Clotet N, Montero M, Font CR, Terron A, Galindo MJ, Martinez O, Ryan P, Omar-Mohamed M, Albendín-Iglesias H, Javier R, Romero A, Vallecillos CG, Calleja MÁ, Hidalgo-Tenorio C.   +19 more
europepmc   +1 more source

Early experience of dolutegravir pharmacokinetics in pregnancy: high maternal levels and significant foetal exposure with twice-daily dosing [PDF]

, 2016
Chaponda, Mas, Khoo, Saye, Lewis, Joseph M, Railton, Eimear, Riordan, Andrew   +4 more
core   +1 more source